Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Study of VST-1001 (Dilute Fluorescein) for Lymphatic Mapping and Localization of Lymph Nodes Draining a Primary Tumor Site in Patients With Clinically Node Negative Breast Cancer

NCT02294565 is registered in ClinicalTrials.gov with Vestan, Inc. as lead sponsor.

NCT NCT02294565
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02294565 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Study of VST-1001 (Dilute Fluorescein) for Lymphatic Mapping and Localization of Lymph Nodes Draining a Primary Tumor Site in Patients With Clinically Node Negative Breast Cancer
Lead sponsor
Vestan, Inc.
Phase
Phase 1/2
Overall status
Unknown status
Start date
June 30, 2014
Completion date
May 31, 2016
Enrollment
147 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer